Hermetica Superfood Encyclopedia
The Short Answer
Trametes meyenii contains phenolic acids, flavonoids, β-glucans, gallic acid, rutin, and carotenoids that exert antioxidant activity through free radical scavenging, immunomodulation via β-glucan receptor engagement, and antimicrobial effects linked to high polyphenol content. In vitro studies report DPPH radical inhibition of 32.62–72.32% and total phenolic concentrations up to 48.71 mg/g in methanolic extracts, with β-glucan content reaching 42% of dry biomass weight, though no human clinical trials have yet validated these effects.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordTrametes meyenii benefits
Trametes meyenii — botanical close-up
Health Benefits
**Antioxidant Defense**: Phenolic compounds including gallic acid (45
72 mg/g) and rutin (12.50 mg/g) donate hydrogen atoms via hydroxyl groups (confirmed by FTIR at 3272 cm⁻¹) to neutralize reactive oxygen species, yielding DPPH inhibition rates of 32.62–72.32% comparable to synthetic antioxidant BHA in vitro.
**Immunomodulation**
High-molecular-weight β-glucans (comprising up to 42% of dried biomass) engage Dectin-1 and CR3 receptors on macrophages and dendritic cells, stimulating innate immune pathways and showing preliminary utility as adjuncts in preclinical cancer immunotherapy models.
**Anti-inflammatory Activity**
Flavonoids and phenolic acids suppress pro-inflammatory mediators; methanolic extracts demonstrated nitric oxide scavenging (NO2 inhibition 34.31–62.30%) in vitro, suggesting inhibition of nitric oxide synthase-driven inflammatory cascades.
**Antimicrobial Properties**
Polyphenol-rich water and methanolic extracts exhibit broad-spectrum antimicrobial activity against pathogenic bacteria and fungi in vitro, with activity attributed to membrane disruption and enzyme inhibition by flavonols and phenolic acids identified via LC-MS.
**Enzymatic Dye Degradation (Laccase Activity)**: T
meyenii produces laccase enzymes capable of oxidatively decolorizing synthetic dyes, with manganese peroxidase activity further enhanced by Mn(II) supplementation, demonstrating biotechnological potential for environmental remediation.
**Carotenoid-Based Cellular Protection**: Detectable β-carotene (8
34 mg/g) and lycopene (6.85 mg/g) contribute to quenching singlet oxygen and lipid peroxyl radicals, with C=C stretching (1640 cm⁻¹) and C-H bending (2925.65 cm⁻¹) confirmed by FTIR spectroscopy.
**Potential Anti-Parasitic Activity**: Saponins (70
6 µg/mL in biomass extracts) and anthraquinones (14.5 µg/mL) are structurally associated with membrane-disrupting and anti-parasitic mechanisms observed in related fungal and plant species, though direct anti-parasitic efficacy in T. meyenii has not yet been confirmed in controlled studies.
Origin & History
Natural habitat
Trametes meyenii is a bracket fungus (polypore) originally described by Klotzsch and reclassified by Lloyd, found growing on decaying hardwood trees across temperate and subtropical forest ecosystems in Europe, Asia, and the Americas. It is closely related to—and taxonomically overlapping with—Trametes versicolor (turkey tail mushroom), leading to frequent synonymous use in ethnobotanical and pharmacological literature. The fungus grows as annual, leathery, fan-shaped fruiting bodies on logs and stumps, thriving in moist, shaded woodland environments, and is harvested both from wild populations and via submerged liquid fermentation cultivation in laboratory and commercial settings.
“Trametes species including T. meyenii occupy a broad place in traditional medicine across East Asia, Europe, and indigenous American cultures, where bracket fungi growing on hardwoods were used as decoctions for general vitality, immune support, and wound healing long before their bioactive constituents were characterized. In East Asian traditions, closely related Trametes versicolor (known as Yun Zhi in Chinese medicine and Kawaratake in Japan) has centuries of documented use as a tonic and anti-cancer adjunct, with formal pharmacopoeial recognition in Chinese herbal medicine. The specific epithet 'meyenii' honors the botanist Johann Meyén, reflecting European natural history traditions of the 19th century, and the species was first formally described by Klotzsch before Lloyd's reclassification into Trametes. Modern ethnobotanical surveys in regions where T. meyenii is endemic document its wild harvesting for folk remedies, though geographic genetic variation and climate influence fruiting body chemistry, complicating standardization of traditional preparations.”Traditional Medicine
Scientific Research
The evidence base for Trametes meyenii specifically is sparse and largely derived by taxonomic inference from the much better-studied Trametes versicolor; no randomized controlled trials or prospective human studies have been conducted using authenticated T. meyenii material. Available data consist entirely of in vitro biochemical assays and preclinical bioactivity screens, including DPPH radical scavenging assays, LC-MS phytochemical profiling identifying 28 phenolic compounds, and submerged cultivation biomass analyses quantifying β-glucan yields. One series of in vitro studies reported total phenolics of 48.71 mg/g and gallic acid at 45.72 mg/g in methanolic extracts, with antioxidant activity comparable to BHA at 0.5 mg/mL test concentrations, but without animal model validation or pharmacokinetic assessment. The overall evidence quality is preliminary and pre-clinical; extrapolation of findings from T. versicolor clinical literature—which includes small human trials for immune support—to T. meyenii requires significant caution given unresolved taxonomic and chemotypic differences between the two species.
Preparation & Dosage
Traditional preparation
**Methanolic Extract (Laboratory Standard)**
5 mg/mL in DPPH antioxidant assays; no validated human dose established
Prepared by solvent extraction followed by rotary evaporation; used at 0..
**Water Decoction (Traditional Preparation)**
Hot water extraction of dried fruiting bodies, consistent with folk medicine practice across Trametes species; phenolic and β-glucan content varies by temperature and extraction duration.
**Submerged Cultivation Biomass Extract**
713 mg/mL and saponins at 70
Liquid fermentation of mycelium yields β-glucan concentrations of 1..6 µg/mL; used in research settings, not yet standardized for supplementation.
**Ethanolic Extract**
Used in phytochemical profiling studies; flavonoid yield 9.50 µg/mL in biomass extracts; no standardized commercial product available.
**Standardized β-Glucan Supplement (Theoretical)**
1–3 g dried extract daily has been used for T
By analogy with T. versicolor products, β-glucan standardization to ≥30–40% of extract weight is biologically plausible; a provisional research dose of . versicolor but is not validated for T. meyenii.
**Timing and Form Notes**
No pharmacokinetic data exist for T. meyenii; general fungal polysaccharide absorption is enhanced when taken with food; freeze-dried powder or hot-water extract formats are most consistent with bioactive preservation.
Nutritional Profile
Trametes meyenii fruiting bodies and mycelial biomass contain a complex matrix of bioactive constituents rather than a conventional macronutrient profile. Total phenolics reach up to 48.71 mg/g (gallic acid equivalents) in methanolic extracts, with flavonoids at 13.13 mg/g (rutin: 12.50 mg/g) and ascorbic acid at 11.03 mg/g. Carotenoids are present as β-carotene (8.34 mg/g) and lycopene (6.85 mg/g), contributing fat-soluble antioxidant capacity with bioavailability dependent on lipid co-ingestion. β-Glucans constitute up to 42% of dried biomass by weight (1.713 mg/mL in liquid extract), representing the dominant polysaccharide fraction with immunological significance. Saponins (70.6 µg/mL) and anthraquinones (14.5 µg/mL) are present in submerged culture extracts. LC-MS profiling identifies 28 phenolic compounds across 11 phenolic acids, 6 flavonols, 6 flavones, and 2 coumarins; conventional macronutrient data (protein, fat, carbohydrate by weight) have not been reported for authenticated T. meyenii material in available literature.
How It Works
Mechanism of Action
Phenolic compounds in Trametes meyenii—particularly gallic acid and rutin—donate electrons via their hydroxyl groups to neutralize DPPH and nitric oxide radicals, a mechanism confirmed spectroscopically by O-H stretching at 3272 cm⁻¹ and C=C aromatic stretching at 1640 cm⁻¹. β-Glucans (1.3/1.6-linked glucose polymers) bind pattern recognition receptors including Dectin-1 on innate immune cells, triggering NF-κB and MAPK signaling cascades that upregulate cytokine production and phagocytosis. Laccase enzymes secreted by the mycelium catalyze single-electron oxidation of phenolic substrates through a type-1 copper active site, enabling degradation of complex aromatic compounds including environmental dyes, with Mn(II) acting as a redox mediator to augment manganese peroxidase co-activity. Saponins and anthraquinones likely interact with membrane sterols of microbial and parasitic cells, altering membrane permeability and disrupting intracellular ion homeostasis, though this mechanism requires direct experimental confirmation in T. meyenii isolates.
Clinical Evidence
No clinical trials have been conducted specifically on Trametes meyenii in human subjects, and no effect sizes, confidence intervals, or patient-level outcomes are available for this species. Preclinical in vitro data establish biologically plausible antioxidant and immunomodulatory activities, but dose-response relationships and systemic bioavailability in humans remain entirely uncharacterized. While Trametes versicolor has been evaluated in small human trials for immune support in cancer patients (e.g., PSK/polysaccharide-K extracts in Japanese oncology research), those findings cannot be directly attributed to T. meyenii without species-authenticated clinical replication. Confidence in any clinical recommendation for T. meyenii is therefore very low, and the compound should be regarded as a research-stage ingredient pending dedicated human pharmacological study.
Safety & Interactions
No formal toxicology studies, maximum tolerated dose data, or adverse event reports have been published specifically for Trametes meyenii, leaving its human safety profile uncharacterized beyond the general tolerance observed for edible Trametes species. The high phenolic and flavonoid content raises theoretical concern for interaction with anticoagulant drugs (e.g., warfarin) and cytochrome P450-metabolized medications, by analogy with other polyphenol-rich botanical extracts, though no pharmacokinetic interaction data exist for T. meyenii specifically. Immunomodulatory β-glucans could theoretically potentiate or interfere with immunosuppressant therapies (e.g., cyclosporine, tacrolimus) in transplant recipients or autoimmune patients, warranting clinical caution. Pregnancy and lactation safety has not been assessed; standard precautionary guidance advises against use during pregnancy and breastfeeding in the absence of controlled safety data. Individuals with mushroom allergies or sensitivities should avoid use, and wild-harvested material carries risks of misidentification and contamination.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Polyporus meyenii KlotzschTrametes meyenii (Trametes meyenii (Berk.) Gilbertson)Trametes meyenii (Klotzsch) Lloydbracket fungusTrametes versicolor (related/synonymous species)
Frequently Asked Questions
What is Trametes meyenii and how does it differ from Trametes versicolor?
Trametes meyenii is a bracket polypore fungus originally described by Klotzsch and reclassified by Lloyd, closely related to and frequently treated as synonymous with Trametes versicolor (turkey tail mushroom) in scientific literature. The two species share overlapping phytochemical profiles including β-glucans, phenolic acids, and flavonoids, but taxonomic and chemotypic differences remain incompletely resolved, meaning research findings from T. versicolor cannot be directly assumed to apply to T. meyenii without species-specific validation.
What are the main bioactive compounds in Trametes meyenii?
The primary bioactive compounds identified in Trametes meyenii extracts include phenolic acids (total phenolics up to 48.71 mg/g), flavonoids (13.13 mg/g), gallic acid (45.72 mg/g), rutin (12.50 mg/g), ascorbic acid (11.03 mg/g), β-carotene (8.34 mg/g), lycopene (6.85 mg/g), saponins (70.6 µg/mL), anthraquinones (14.5 µg/mL), and β-glucans comprising up to 42% of dried biomass. LC-MS analysis has identified 28 individual phenolic compounds across phenolic acid, flavonol, flavone, and coumarin subclasses.
Has Trametes meyenii been tested in human clinical trials?
No human clinical trials have been conducted specifically on Trametes meyenii; all available evidence is limited to in vitro biochemical assays and preclinical bioactivity studies using methanolic, ethanolic, and water-based extracts. Clinical evidence from related species—particularly Trametes versicolor polysaccharide-K (PSK) trials in Japanese oncology—cannot be directly attributed to T. meyenii without authenticated species-specific human studies. The ingredient should currently be considered research-stage with a preliminary evidence classification.
What is the recommended dosage of Trametes meyenii supplements?
No validated human dosage has been established for Trametes meyenii because no clinical pharmacokinetic or dose-finding studies have been conducted. Laboratory studies use concentrations such as 0.5 mg/mL for antioxidant assays, which cannot be directly translated to oral supplement doses. By general analogy with Trametes versicolor research, dried extract doses of 1–3 g daily have been explored for immune support, but this remains unvalidated for T. meyenii specifically and should not be used as a clinical recommendation.
Is Trametes meyenii safe to take, and are there any drug interactions?
The safety profile of Trametes meyenii in humans has not been formally evaluated in toxicology or clinical studies, and no specific adverse events, drug interactions, or contraindications have been reported to date. Theoretical interaction risks exist with anticoagulant medications (e.g., warfarin) due to high polyphenol content, and immunomodulatory β-glucans may interfere with immunosuppressant therapy in transplant or autoimmune patients. Pregnant and breastfeeding individuals should avoid use pending safety data, and general precautions regarding mushroom allergies and wild-harvest contamination apply.
How do the antioxidant compounds in Trametes meyenii compare to other medicinal mushrooms?
Trametes meyenii contains notably high phenolic content, with gallic acid at 45.72 mg/g and rutin at 12.50 mg/g, delivering DPPH inhibition rates of 32.62–72.32% that rival synthetic antioxidant BHA in laboratory testing. While other medicinal mushrooms like Ganoderma lucidum and Lentinula edodes contain antioxidants, Trametes meyenii's specific phenolic profile and measured potency make it distinctive for antioxidant support. The hydrogen-donating capacity of its hydroxyl groups (confirmed by FTIR spectroscopy) provides a mechanistic advantage in neutralizing reactive oxygen species.
What role do β-glucans play in Trametes meyenii's immune-supporting effects?
Trametes meyenii contains high-molecular-weight β-glucans comprising up to 42% of the dried mushroom material, which are the primary compounds responsible for its immunomodulatory activity. These β-glucans are recognized by immune receptors on macrophages and other immune cells, promoting a balanced inflammatory response and supporting natural defense mechanisms. The concentration and molecular weight of these polysaccharides directly correlate with the mushroom's traditional use in immune support across Asian herbal medicine systems.
Can Trametes meyenii be used alongside other medicinal mushrooms for enhanced benefits?
Trametes meyenii can typically be combined with complementary mushrooms like Ganoderma lucidum (reishi) or Cordyceps species, as they contain different primary bioactive compounds and mechanisms of action that may provide synergistic benefits. However, combining multiple mushroom supplements may increase overall polysaccharide and bioactive compound intake, so users should monitor total dosage and consult a healthcare provider. The phenolic-rich antioxidant profile of Trametes meyenii pairs particularly well with β-glucan-focused mushrooms to support both antioxidant and immune-modulating pathways.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w trametes-meyenii-trametes-meyenii-klotzsch-lloyd curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
